Congratulations to Laekna Inc. (2105.HK) on its Successful Listing

 

 

Congratulations to Laekna Inc. (2105.HK) on its Successful Listing on the Mainboard of HKSE on 29 June 2023.

 

Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company which has 2 Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The other Core Product LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer.

 

With potentially better clinical efficacy and favorable safety profile of ATP competitive AKT inhibitor LAE002 in registrational clinical trials, favorable efficacy profile for prostate cancer of CYP17A1/CYP11B2 inhibitor LAE001 as well as deep understanding into fundamental disease biology and clinical practice from their R&D team members, these competitive advantages empower the company’s internal discovery, business development and translational research.

 

With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services related to preferred stock, employee stock option and intangible asset impairment testing for financial reporting purposes. 

 

Congratulations again to Laekna Inc. (2105.HK) on its successful listing. The issue price is HKD 12.41 per share, and the amount of funds raised is HKD 791 million.